Job Harenberg

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi request reprint Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis
    J Harenberg
    Department of Clinical Pharmacology Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Germany
    Int Angiol 31:330-9. 2012
  2. pmc A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study
    Oliver Dorsch
    KfH Kuratorium für Dialyse und Nierentransplantation e, V, KfH Nierenzentrum, Kronach, Germany
    BMC Nephrol 13:50. 2012
  3. doi request reprint Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples
    Job Harenberg
    Department of Clinical Pharmacology Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 39:66-71. 2013
  4. doi request reprint Clinical trials with new oral anticoagulants. Additive value of indirect comparisons also named network meta-analyses
    J Harenberg
    Department of Clinical Pharmacology, Medical Faculty Mannheim, University of Heidelberg, Maybachstr 14, 68169 Mannheim, Germany
    Hamostaseologie 33:62-70. 2013
  5. doi request reprint Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery
    Job Harenberg
    Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Thromb Haemost 108:903-12. 2012
  6. doi request reprint Measurement of the new anticoagulants
    Job Harenberg
    University Hospital, Mannheim, Germany
    Thromb Res 129:S106-13. 2012
  7. doi request reprint Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization
    Job Harenberg
    Clinical Pharmacology, Faculty of Medicine Mannheim, Mannheim, Germany
    Clin Appl Thromb Hemost 17:E158-64. 2011
  8. doi request reprint Determination of dabigatran in human plasma samples
    Job Harenberg
    Department of Clinical Pharmacology, Medical Faculty, Mannheim, Ruprecht Karls University Heidelberg, Maybachstrasse, Mannheim, Germany
    Semin Thromb Hemost 38:16-22. 2012
  9. doi request reprint Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban
    Job Harenberg
    Department of Clinical Pharmacology, Ruprecht Karls University Heidelberg, Heidelberg, Germany
    Blood Coagul Fibrinolysis 22:637-41. 2011
  10. doi request reprint New anticoagulants in atrial fibrillation
    Job Harenberg
    Clinical Pharmacology Mannheim, Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 35:574-85. 2009

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis
    J Harenberg
    Department of Clinical Pharmacology Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Germany
    Int Angiol 31:330-9. 2012
    ..A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation...
  2. pmc A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis--the membrane study
    Oliver Dorsch
    KfH Kuratorium für Dialyse und Nierentransplantation e, V, KfH Nierenzentrum, Kronach, Germany
    BMC Nephrol 13:50. 2012
    ..Adequate anticoagulation is prerequisite for effective hemodialysis to prevent clotting in the extracorporeal circuit. We aimed providing first data on the efficacy and safety of the low-molecular-weight heparin certoparin in this setting...
  3. doi request reprint Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples
    Job Harenberg
    Department of Clinical Pharmacology Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 39:66-71. 2013
    ..Here we describe results of a POC qualitative assay using urine samples from patients on treatment with dabigatran and rivaroxaban...
  4. doi request reprint Clinical trials with new oral anticoagulants. Additive value of indirect comparisons also named network meta-analyses
    J Harenberg
    Department of Clinical Pharmacology, Medical Faculty Mannheim, University of Heidelberg, Maybachstr 14, 68169 Mannheim, Germany
    Hamostaseologie 33:62-70. 2013
    ....
  5. doi request reprint Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery
    Job Harenberg
    Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Thromb Haemost 108:903-12. 2012
    ....
  6. doi request reprint Measurement of the new anticoagulants
    Job Harenberg
    University Hospital, Mannheim, Germany
    Thromb Res 129:S106-13. 2012
    ..Point of care methods from plasma or urine for the new oral anticoagulants would improve patient care. First data demonstrate the feasibility of such assays in urine...
  7. doi request reprint Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization
    Job Harenberg
    Clinical Pharmacology, Faculty of Medicine Mannheim, Mannheim, Germany
    Clin Appl Thromb Hemost 17:E158-64. 2011
    ..Ideally, the differences between the actual recommendations and guidelines for the production of generic version of LMWHs should be harmonized...
  8. doi request reprint Determination of dabigatran in human plasma samples
    Job Harenberg
    Department of Clinical Pharmacology, Medical Faculty, Mannheim, Ruprecht Karls University Heidelberg, Maybachstrasse, Mannheim, Germany
    Semin Thromb Hemost 38:16-22. 2012
    ..This article reports the effects of dabigatran on clinical routine assays and the potential usefulness for determination in special risk groups of patients when overdose or lack of compliance are suspected...
  9. doi request reprint Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban
    Job Harenberg
    Department of Clinical Pharmacology, Ruprecht Karls University Heidelberg, Heidelberg, Germany
    Blood Coagul Fibrinolysis 22:637-41. 2011
    ..In conclusion, the determination of an ISI for rivaroxaban using a WHO thromboplastin reagent is required for commercial thromboplastin reagents. The manual Kolle-Hook method and an ordinary linear regression analysis should be adopted...
  10. doi request reprint New anticoagulants in atrial fibrillation
    Job Harenberg
    Clinical Pharmacology Mannheim, Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 35:574-85. 2009
    ..Indirect systemic and oral direct factor Xa and oral direct thrombin inhibitors are currently being developed for the prevention of embolism in patients with AF...
  11. ncbi request reprint Recommendations on biosimilar low-molecular-weight heparins
    J Harenberg
    Clinical Pharmacology, Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    J Thromb Haemost 7:1222-5. 2009
    ....
  12. doi request reprint Development of idraparinux and idrabiotaparinux for anticoagulant therapy
    Job Harenberg
    Ruprecht Karls University Heidelberg, Maybachstrasse 14, D 68169 Mannheim, Germany
    Thromb Haemost 102:811-5. 2009
    ..This compound is currently investigated in clinical trials for prevention of recurrent VTE in patients with acute pulmonary embolism. The future of idrabiotaparinux depends also on the safety and efficacy of avidin...
  13. doi request reprint Future of anticoagulant therapy
    Job Harenberg
    Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany
    Cardiovasc Ther 29:291-300. 2011
    ..The future of the new anticoagulants will depend on the demonstration of their safety, efficacy, and health cost savings compared to the conventional antithrombotics...
  14. doi request reprint [Anticoagulation in the elderly]
    J Harenberg
    Klinische Pharmakologie Mannheim, Ruprecht Karls Universitat Heidelberg, Maybachstraße 14, 68169, Mannheim
    Internist (Berl) 51:1446-55. 2010
    ..Further details of anticoagulant therapy should be in agreement with the national or international recommendations...
  15. doi request reprint Overview on guidelines and recommendations for generic low-molecular-weight heparins
    Job Harenberg
    Clinical Pharmacology, Faculty of Medicine Mannheim, Mannheim, Germany
    Thromb Res 127:S100-4. 2011
    ..The present review describes the differences between the actual guidelines and recommendations for the production of generic version of LMWHs...
  16. pmc New anticoagulants - promising and failed developments
    Job Harenberg
    Clinical Pharmacology, Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Br J Pharmacol 165:363-72. 2012
    ..Quality-adjusted life years costs and incremental cost-effectiveness ratios are relatively high at present, but may decrease after approval of more new anticoagulants for additional indications...
  17. doi request reprint Development of new anticoagulants: present and future
    Job Harenberg
    Clinical Pharmacology, Faculty of Medicine Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 34:779-93. 2008
    ..This overview describes the results of some recent studies of these inhibitors of blood coagulation...
  18. pmc Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
    Job Harenberg
    Department of Clinical Pharmacology, University Heidelberg, Maybachstrasse 14, Mannheim, Germany
    J Thromb Thrombolysis 32:267-71. 2011
    ..3 ± 11.4% using the original data to 3.8 ± 2.2% using the calculated data (P < 0.0001). The robustness of the chromogenic assay (method B) remains to be corroborated in interlaboratory comparisons...
  19. ncbi request reprint Idraparinux and idrabiotaparinux
    Job Harenberg
    Clinical Pharmacology, Faculty of Medicine Mannheim, Ruprecht Karls University Heidelberg, Maybachstrasse 14, D 68169 Mannheim, Germany
    Expert Rev Clin Pharmacol 3:9-16. 2010
    ..The future of idrabiotaparinux depends on the demonstration of its safety and efficacy. Avidin also has to demonstrate its efficacy and safety after single and repeated injections...
  20. doi request reprint Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa
    Job Harenberg
    Clinical Pharmacology Mannheim, Vascular Pharmacotherapy, Faculty of Medicine, University of Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 34:39-57. 2008
    ....
  21. ncbi request reprint Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model
    Job Harenberg
    4th Department of Clinical Medicine, University Hospital Mannheim, University of Heidelberg, Germany
    Semin Thromb Hemost 28:379-82. 2002
    ..The data show that DTIs inhibit both fibrin formation and platelet activation, which is of clinical relevance especially for melagatran...
  22. doi request reprint Determination of rivaroxaban in human plasma samples
    Job Harenberg
    Department of Clinical Pharmacology, Faculty of Medicine, Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 38:178-84. 2012
    ..Moreover, clinical trials are needed to determine the relationship of assay results with bleeding or thrombotic complications...
  23. ncbi request reprint Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban
    Job Harenberg
    IV Department of Medicine, University Hospital Mannheim, Ruprecht Karls University Heidelberg, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany
    J Thromb Thrombolysis 19:65-9. 2005
    ....
  24. ncbi request reprint Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran
    Job Harenberg
    IV Department of Medicine, University Hospital, Mannheim, Germany
    Int J Toxicol 25:165-9. 2006
    ..0002). The authors conclude that ALAT increases dose dependently during therapy with ximelagatran. The less frequent and lower increase of ASAT values compared to ALAT values indicates a nontoxic effect of ximelagatran on liver cells...
  25. ncbi request reprint Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation
    Tivadar Fenyvesi
    Fourth Department of Medicine, University Hospital Mannheim, Ruprecht Karls University Heidelberg, Theodor Kutzer Ufer 1, 68167 Mannheim, Germany
    Clin Chem 48:1791-4. 2002
  26. ncbi request reprint Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors
    Tivadar Fenyvesi
    IV Department of Medicine, University Hospital Mannheim, Mannheim, Germany
    Blood Coagul Fibrinolysis 15:605-11. 2004
    ....
  27. ncbi request reprint Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin
    Job Harenberg
    IV Dept of Medicine, University Hospital, Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Haematologica 88:1157-62. 2003
    ..We investigated whether these findings hold for a particular LMWH by pooling the results of two independent studies...
  28. ncbi request reprint Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran
    Job Harenberg
    Fourth Department of Medicine, University Hospital, Mannheim, Germany
    Isr Med Assoc J 4:1003-5. 2002
    ..Venous thromboembolic diseases are treated initially with low molecular weight heparin followed by oral coumarins...
  29. doi request reprint Determination of the anticoagulant effects of new oral anticoagulants: an unmet need
    Job Harenberg
    Clinical Pharmacology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Maybachstr, 14, D 68169 Mannheim, Germany
    Expert Rev Hematol 5:107-13. 2012
    ..Standardization of methods, development of point-of-care tests and identification of patient groups is ongoing...
  30. doi request reprint Determination of direct oral anticoagulants from human serum samples
    Job Harenberg
    Department of Clinical Pharmacology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
    Semin Thromb Hemost 40:129-34. 2014
    ..Specific adaption to automated coagulation platforms may improve the performance of the assays from serum samples. ..
  31. ncbi request reprint Monitoring of anticoagulant effects of direct thrombin inhibitors
    Tivadar Fenyvesi
    4th Department of Medicine, University Hospital, Mannheim, Germany
    Semin Thromb Hemost 28:361-8. 2002
    ..PiCT yields comparable results with direct thrombin inhibitors and UFH. This method could therefore be suitable for monitoring both drug groups...
  32. doi request reprint Interaction of heparin with cationic molecular probes: probe charge is a major determinant of binding stoichiometry and affinity
    Helga Szelke
    University of Heidelberg, Inorganic Chemistry Institute, 69120 Heidelberg, Germany
    Bioorg Med Chem Lett 20:1445-7. 2010
    ..The polyanionic polysaccharide strands of heparin bind more probe molecules per sugar unit when the charge of the latter is low, and stability of the probe-heparin complex increases with increasing probe charge...
  33. ncbi request reprint Association of changes in D-dimer and other coagulation markers with changes in Marder score after treatment of acute venous thrombosis
    Job Harenberg
    Forth Department of Medicine, University Hospital, Faculty of Clinical Medicine Mannheim of the Ruprecht Karls, University of Heidelberg, Mannheim, Germany
    J Thromb Thrombolysis 14:73-8. 2002
    ..An association between changes in these markers and changes in venographic Marder scores in patients with acute deep vein-thrombosis treated with low-molecular-weight (LMWH) or unfractionated heparin (UFH) has not been reported...
  34. ncbi request reprint Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time
    Job Harenberg
    Medizinische Klinik, Universitatsklinikum Mannheim, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
    Semin Thromb Hemost 33:503-7. 2007
    ..We conclude that PiCT is a suitable assay to determine the anticoagulant effects of these two new FXa inhibitors in patients receiving treatment with these compounds...
  35. ncbi request reprint Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time
    Tivadar Fenyvesi
    Fourth Department of Medicine, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Thromb Res 111:89-94. 2003
    ..Direct thrombin inhibitors (DTI) prolong the ecarin clotting time (ECT). Oral anticoagulants (OA) decrease prothrombin levels and thus interact with actions of DTIs on the ECT method during concomitant therapy...
  36. doi request reprint Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials
    Job Harenberg
    4th Department of Medicine, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Eur J Clin Pharmacol 64:555-63. 2008
    ..To gather information on anticoagulant effects after the termination of long-term therapy with idraparinux...
  37. ncbi request reprint [Dysphagia after taking an acetaminophen-tablet during oral anticoagulation]
    K M Bauer
    IV Medizinische Klinik, Universitätsklinikum Mannheim der Ruprecht Karls Universität Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim
    Internist (Berl) 46:1394-8. 2005
    ..As well as the application of unique guidelines on endoscopy during oral anticoagulation new future oral anticoagulants with lower half-life may help to shorten suffering of patients...
  38. ncbi request reprint Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Martin Krejczy
    Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht Karls University Heidelberg, Maybachstrasse 14, 68169, Mannheim, Germany
    J Thromb Thrombolysis 37:507-23. 2014
    ..These results from clinical studies (efficacy) remain to be confirmed under real life conditions (effectiveness). ..
  39. doi request reprint Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model
    Khaled Abduljalil
    Department of Pharmacology, Clinical Pharmacology Unit, University Hospital, University of Cologne, Gleueler Straße 24, 50931 Cologne, Germany
    Clin Pharmacokinet 52:359-71. 2013
    ..The aim of the present study was to quantify major sources of interindividual variability separately on the pharmacokinetics and pharmacodynamics of phenprocoumon using a population pharmacokinetic-pharmacodynamic model...
  40. ncbi request reprint Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis
    Job Harenberg
    4th Department of Medicine, University Hospital Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Curr Opin Pulm Med 8:383-8. 2002
    ..Major bleeding was not related to the body weight in either treatment group. Treatment of acute DVT in adults with fixed dose of 2 x 8000 aXa IU LMWH Certoparin is more effective and safer than heparin...
  41. ncbi request reprint Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative
    Job Harenberg
    1st Department of Medicine, Medical University Clinic, Mannheim, Germany
    Semin Thromb Hemost 28:343-54. 2002
    ..F-labeled heparin was displaced by unlabeled heparin from all three populations of leukocytes. Binding of heparin to leukocytes may play an important role in inflammation and atherosclerosis...
  42. doi request reprint Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy
    Shabnam Zolfaghari
    Department of Clinical Pharmacology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
    Semin Thromb Hemost 40:121-8. 2014
    ..This tool may be useful for practitioners and health-care professionals to support patient adherence to therapy, and thereby increase treatment effectiveness...
  43. ncbi request reprint [Atrial fibrillation and thromboprophylaxis in elderly patients]
    I Jörg
    IV Medizinische Klinik, Universitätsklinik Mannheim, Fakultät für Klinische Medizin der Universität Heidelberg, Mannheim, Germany
    Z Kardiol 94:87-94. 2005
    ..6%/year for study Sportif III and Sportif V). All bleeding complications occurred less frequently under therapy with ximelagatran. This could be of importance for elderly patients with risk factors for bleeding or risk of falling...
  44. ncbi request reprint Development of a high-pressure liquid chromatography method for diagnosis of heparin-induced thrombocytopenia
    Sandra Koch
    IV Department of Medicine, University Hospital, Faculty of Clinical Medicine Mannheim of the Ruprecht Karls University of Heidelberg, Heidelberg, Germany
    Am J Clin Pathol 117:900-4. 2002
    ..5 ng/mL of serotonin were released. The HPLC method permits a rapid, sensitive, and quantitative determination of serotonin released from donor platelets for laboratory confirmation of HIT...
  45. ncbi request reprint Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes
    J Harenberg
    Department of Internal Medicine and Geriatrics, University Hospital, Mannheim, Germany
    J Thromb Haemost 2:547-50. 2004
  46. ncbi request reprint Emerging concepts in thromboprophylaxis
    J Harenberg
    Fourth Department of Internal Medicine, University Hospital of Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Pathophysiol Haemost Thromb 32:398-400. 2002
  47. ncbi request reprint Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia
    J Harenberg
    Department of Medicine I, University Hospital, Faculty of Clinical Medicine Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany
    Br J Haematol 109:360-3. 2000
    ..Baseline ecarin clotting times showed high variability. Patients with antibodies to hirudin may be re-exposed but anticoagulant monitoring is mandatory...
  48. ncbi request reprint [Ximelagatran for treatment of venous thromboembolism]
    J Harenberg
    IV Medizinische Klinik, Universitatsklinikum, Mannheim, Germany
    Hamostaseologie 22:25-9. 2002
    ..Ximelagatran is currently investigated versus placebo to demonstrate a reduced recurrence rate of venous thromboembolism over a period of 18 months...
  49. ncbi request reprint Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers
    U Hoffmann
    Department of Medicine, University Hospital, Mannheim, Germany
    Blood Coagul Fibrinolysis 13:289-96. 2002
    ..1 and 3.6% following i.v. and s.c. administration, respectively. Differences in the pharmacodynamic parameters of the assays indicate specific biological actions of high and low molecular sacharide chains of the LMWH...
  50. ncbi request reprint Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators
    J Harenberg
    Dept of Medicine, University Hospital, Mannheim, Germany
    Thromb Haemost 83:652-6. 2000
    ..Therefore a fixed LMWH dose, independent of body-weight, might rationalize initial treatment for venous thromboembolism...
  51. ncbi request reprint Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model
    K Zokai
    First Department of Medicine, University Hospital, Mannheim, Germany
    Semin Thromb Hemost 27:531-6. 2001
    ....
  52. ncbi request reprint Heparin-induced thrombocytopenia: pathophysiology and new treatment options
    J Harenberg
    4th Dept of Medicine, University Hospital Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany
    Pathophysiol Haemost Thromb 32:289-94. 2002
    ..Treatment options are danaparoid, r-hirudin, bivalirudin, argatroban, dextransulfate, and dermatansulfate. In future, fondaparinux and ximelagatran may be considered for treatment...
  53. ncbi request reprint [Heparin, thrombin and Factor Xa inhibitors]
    J Harenberg
    IV Medizinische Klinik, Universitatsklinikum, Mannheim, Germany
    Hamostaseologie 24:261-78. 2004
    ..g. activated protein C in septicaemia). New anticoagulant methods are developed to improve and specify the anticoagulant effect of anticoagulants in thromboembolic diseases...
  54. ncbi request reprint Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method
    T Fenyvesi
    Fourth Medical Department, University Hospital, Mannheim, Germany
    Pathophysiol Haemost Thromb 32:174-9. 2002
    ..PiCT ratio reduces differences between both groups with UFH, and argatroban inhibitor-receptor-binding mode plays a role in interaction patterns...